Researchers evaluated a fully automated plasma biomarker panel to detect early amyloid-β accumulation in cognitively unimpaired adults at risk for Alzheimer’s disease. Plasma p-tau217/Aβ42 emerged as the most robust and accurate blood-based marker for identifying preclinical amyloid pathology.